|
Summary
2008, Vol. 24, No. 2, Pages 369-376
Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE studyAnne DornhorstABSTRACT Objective: PREDICTIVE is a multi-national, prospective, observational study, assessing the safety and efficacy of insulin detemir in patients with diabetes. Research design and methods: The European cohort includes 20 Results: SADRs were reported by 62 (2.0%) patients previously receiving NPH insulin, 45 (2.7%) patients previously receiving insulin glargine and seven (1.2%) patients previously receiving human basal-bolus insulins. Major hypoglycaemia was significantly reduced in NPH insulin (55%), insulin glargine (51%), and human basal-bolus insulin groups (54%; p < 0.0001 for all). Total and nocturnal hypoglycaemic episodes were also significantly reduced in all groups ( Conclusions: In this open-label, prospective, observational study, insulin detemir basal-bolus therapy improved glycaemic control and reduced hypoglycaemia with weight neutrality in type 1 patients in actual clinical practice. Forward Links to Citing ArticlesSelim Kurtoglu, Mehmet Emre Atabek, Ceyhun Dizdarer, Ozgur Pirgon, Pinar Isguven, Sevil Emek. (2009) Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE™ observational study. Pediatric Diabetes Online publication date: 1-Mar-2009. CrossRef Allen B King. (2009) Insulin detemir: a better basal insulin for the management of diabetes?. Expert Review of Endocrinology & Metabolism 4:1, 15-23 Online publication date: 1-Feb-2009. CrossRef S. Sreenan, A. Virkamäki, K. Zhang, J. B. Hansen. (2009) Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study. International Journal of Clinical Practice 62:12, 1971-1980 Online publication date: 1-Jan-2009. CrossRef (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:9, i-xvi Online publication date: 1-Oct-2008. CrossRef Users who read this article also read:
|
|




Professor Seamus Sreenan, Dept of Endocrinology, Connolly Hospital, Blanchardstown, Dublin 15, Ireland. Tel.: +353 1 646 5748, Fax: +353 1 646 5310,
531 patients with diabetes (7420 type 1) from 11 countries. A subgroup of 4782 type 1 patients were transferred from a basal-bolus regimen with NPH insulin (n = 3117) or insulin glargine (n = 1665) to insulin detemir basal-bolus therapy; or from a human insulin basal-bolus regimen (n = 570) to insulin detemir/insulin aspart (part of the pre-study NPH group). Mean follow-up was 14.4 weeks. The primary endpoint was serious adverse drug reactions (SADRs), including major hypoglycaemia. Secondary endpoints were: incidence of overall and nocturnal hypoglycaemia; haemoglobin A1c (HbA1c); fasting glucose; within-patient fasting glucose variability; and change in body weight.
TOC Alert